Clinical Trials Logo

Progression-free Survival clinical trials

View clinical trials related to Progression-free Survival.

Filter by:

NCT ID: NCT03100955 Recruiting - Clinical trials for Progression Free Survival

A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer

Start date: March 1, 2017
Phase: Phase 3
Study type: Interventional

To establish the progression free survival in patients with extensive stage small cell lung cancer treated with cisplatin and etoposide plus or not apatinib

NCT ID: NCT02959749 Completed - Clinical trials for Progression Free Survival

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Start date: August 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Acquired epidermal growth factor receptor (EGFR) T790M mutation is the most common genetic change after resistant to first generation EGFR tyrosine kinase inhibitor (EGFR TKI) in non-small cell lung cancer. After a 10 to 14 months median progression-free survival with the treatment of first generation EGFR TKI, half of patients will get disease progression.For patients progression after treated with first line EGFR TKI and second line double bullets chemotherapy or chemotherapy then EGFR TKI, optimal third line therapy is quite critical important for benefit patients' survival. We conducted this study was aimed to compare the efficacy and toxicity between osimertinib and docetaxel-bevacizumab as the third line therapy in patients with local advanced or metastatic non-squamous cell lung cancer.

NCT ID: NCT01453257 Completed - Clinical trials for Progression Free Survival

Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients

TT
Start date: October 2009
Phase: Phase 2
Study type: Interventional

Treatment options for patients with colorectal cancer (CRC) have increased in the last years. However, there are no validated prospective molecular markers in CRC to select which agents are better to treat any individual case. The conventional first-line treatment in CRC patients in clinical studies get a proportion of patients free of progression at 12 months ranging from 35-40% with a median of 9 months of free disease progression. The aim of this study is to demonstrate that the identification of therapeutic targets in real time and their prospectively use to customize the treatment get a proportion of colorectal metastatic patients patients free of progression disease at 12 months of 50%.

NCT ID: NCT00944918 Completed - Clinical trials for Progression-free Survival

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

Start date: December 2008
Phase: Phase 3
Study type: Interventional

A partially-blind, randomised, multicentre phase III trial of Faslodex plus concomitant Arimidex versus Faslodex plus Arimidex-Placebo versus exemestane in postmenopausal locally advanced / metastatic breast cancer patients who have progressed on NSAIs. Randomisation to Faslodex ± Arimidex / Arimidex-Placebo or exemestane will be open (1:1:1). For Faslodex treated patients the randomisation to Arimidex or Arimidex-Placebo will be double-blind.